MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/gutjnl-2016-311739

Медицинская библиотека · Gut · 2016

Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Jendrek Sebastian Torben, Gotthardt Daniel, Nitzsche Thomas, Widmann Laila, Korf Tobias, Michaels Maike Anna, Weiss Karl-Heinz, Liaskou Evaggelia, Vesterhus Mette, Karlsen Tom Hemming, Mindorf Swantje, Schemmer Peter, Bär Florian, Teegen Bianca, Schröder Torsten, Ehlers Marc, Hammers Christoph Matthias, Komorowski Lars, Lehnert Hendrik, Fellermann Klaus, Derer Stefanie, Hov Johannes Roksund, Sina Christian

СтатьяВалидационное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

Pancreatic autoantibodies (PABs), comprising antibodies against glycoprotein 2 (anti-GP2), are typically associated with complicated phenotypes in Crohn's disease, but have also been observed with variable frequencies in patients with UC. In a previous study, we observed a high frequency of primary sclerosing cholangitis (PSC) in patients with anti-GP2-positive UC. We therefore aimed to characterise the role of anti-GP2 in PSC.

DESIGN

In an evaluation phase, sera from 138 well-characterised Norwegian patients with PSC were compared with healthy controls (n=52), and patients with UC without PSC (n=62) for the presence of PABs by indirect immunofluorescence. Further, 180 German patients with PSC served as a validation cohort together with 56 cases of cholangiocarcinoma without PSC, 20 of secondary sclerosing cholangitis (SSC) and 18 of autoimmune hepatitis.

RESULTS

Anti-GP2 IgA specifically occurred at considerable rates in large bile duct diseases (cholangiocarcinoma=36%, PSC and SSC about 50%). In PSC, anti-GP2 IgA consistently identified patients with poor survival during follow-up (Norwegian/German cohort: p Log Rank=0.016/0.018). Anti-GP2 IgA was associated with the development of cholangiocarcinoma in both PSC cohorts, yielding an overall OR of cholangiocarcinoma in patients with anti-GP2 IgA-positive PSC of 5.0 (p=0.001). Importantly, this association remained independent of disease duration, bilirubin level and age.

CONCLUSIONS

Anti-GP2 IgA can be hypothesised as a novel marker in large bile duct diseases. In particular, in PSC, anti-GP2 IgA identified a subgroup of patients with severe phenotype and poor survival due to cholangiocarcinoma. Anti-GP2 IgA may therefore be a clinically valuable tool for risk stratification in PSC.

Для цитирования: Jendrek Sebastian Torben, Gotthardt Daniel, Nitzsche Thomas, Widmann Laila, Korf Tobias, Michaels Maike Anna, Weiss Karl-Heinz, Liaskou Evaggelia, Vesterhus Mette, Karlsen Tom Hemming, Mindorf Swantje, Schemmer Peter, Bär Florian, Teegen Bianca, Schröder Torsten, Ehlers Marc, Hammers Christoph Matthias, Komorowski Lars, Lehnert Hendrik, Fellermann Klaus, Derer Stefanie, Hov Johannes Roksund, Sina Christian. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.. Gut. 2016. DOI: 10.1136/gutjnl-2016-311739.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.